High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.

To present mature results of high-dose-rate brachytherapy (HDR-BT) as monotherapy for intermediate- and high-risk prostate cancer.

From 1995 through 2012, 190 patients, 79 with intermediate-risk and 111 with high-risk prostate cancer, were treated with HDR-BT alone using 48 Gy/8 fractions, 54 Gy/9 fractions, or 45.

5 Gy/7 fractions over 4 to 5 days Neoadjuvant with or without adjuvant androgen deprivation therapy was administered to 139 patients, 35 intermediate- and 104 high-risk

Median follow-up time was 92 months (range, 10-227 months), with a minimum of 2 years for surviving patients Respective rates of cause-specific survival, overall survival, metastasis-free survival, and biochemical no evidence of disease for the intermediate-risk patients were 100%, 100%, 96%, and 93% at 5 years, and 100%, 96%, 91%, and 91% at 8 years Corresponding rates for the high-risk patients were 97%, 93%, 84%, and 81% at 5 years, and 93%, 81%, 74%, and 77% at 8 years The cumulative incidence of late grade 2 to 3 genitourinary toxicity was 5% at 5 years and 10% at 8 years, and that of late grade 3 was 0 at 5 years and 1% at 8 years The cumulative incidence of late grade 2-3 gastrointestinal toxicity was 4% at 5 years and 6% at 8 years, and that of late grade 3 was 0 at 5 years and 2% at 8 years No grade 4 or 5 toxicity was detected

Our single-institution study with a median 8-year follow-up showed that HDR-BT as monotherapy was safe and effective for patients with intermediate- and high-risk prostate cancer

International journal of radiation oncology, biology, physics 2015 Jun 03 [Epub ahead of print]

Yasuo Yoshioka, Osamu Suzuki, Fumiaki Isohashi, Yuji Seo, Hirofumi Okubo, Hiroko Yamaguchi, Michio Oda, Yuki Otani, Iori Sumida, Motohide Uemura, Kazutoshi Fujita, Akira Nagahara, Takeshi Ujike, Atsunari Kawashima, Ken Yoshida, Hideya Yamazaki, Norio Nonomura, Kazuhiko Ogawa

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan Electronic address: yoshioka@radonc med osaka-u ac jp , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka Medical College, Osaka, Japan , Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan , Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan , Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan

PubMed